The FDA approved Larotrectinib which is a cancer drug therapy that is fully independent of the cancer site origin, which targets genetic biomarkers. However the new cancer therapy will not be available to all cancer patients as it targets cancer with an extremely rare genetic finding but it represents the continual advancement of treatments that targets the genetics of the cancer rather than the origin of the tumor. For more information about
this see the following link
https://www.practiceupdate.com/c/76800/1/1/?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=mty0mzmymjiwnjaws0&lid=10332481